History of Anaplasmosis Vaccine
History Of Anaplasmosis Vaccine By D. Gene Luther, D.V.M., Ph.D.
UNIVERSITY PRODUCTS, L.L.C.
DR. D. GENE LUTHER
Cellular # 225-266-8375

425 Woodstone Drive
Baton Rouge, LA 70808
1-800-308-5242
225-769-4146
docndoc@aol.com

Our Anaplasmosis Vaccine was developed at Louisiana State University, Agriculture Center's Veterinary Science Department by a team of three scientists. The research team was composed of L.T. Hart, Ph.D., W.J. Todd, Ph.D., and D. G. Luther, D.V.M., Ph.D. The research was done in the late 1980s and early 1990s. The study lead to a patent for the process of separating the Anaplasma marginale initial bodies from the red blood cell antigens of bovine blood. A study of the purified Anaplasma marginale initial bodies and several different adjuvants was completed to see which product would provide protection for an infectious Anaplasmosis challenge in mature bovine. One adjuvant gave excellent protection against a virulent challenge and was selected the adjuvant to be used in our vaccine.

Louisiana State University licensed the Anaplasmosis Vaccine to Pitman-Moore. Pitman-Moore asked our research team to help them take the vaccine through the USDA licensing process. While the USDA efficacy and safety studies were ongoing Mallinckrodt bought Pitman-Moore. Mallinckrodt finished the USDA licensing process and marketed the vaccine for three years as Plazvax. Mallinckrodt was bought by Schering-Plough. Schering-Plough elected not to produce and market Plazvax. Schering-Plough's decision not to produce and market Plazvax resulted in no commercially available vaccine for Anaplasmosis.

Dairymen in Florida contacted Dr. Luther and asked if he could make the vaccine and he told them that he could but the USDA would not allow him to ship or sell the vaccine. They asked if Dr. Luther would make the vaccine for them if they could get USDA approval and Dr. Luther agreed to make the vaccine. The USDA approved to production and sale of the vaccine as an Experimental Anaplasmosis Vaccine to veterinarians in:
 
Arkansas,
California,
Florida,
Georgia,
Idaho,
Indiana,
Illinois,
Iowa,
Kansas,
Kentucky,
Louisiana,
Maryland,
Mississippi,
Missouri,
Nebraska,
Nevada,
North Dakota,
Ohio,
Oklahoma,
Oregon,
South Carolina,
Tennessee,
Texas,
Virginia,
West Virgina,
Wisconsin,
Puerto Rico.

The vaccine is not licensed by the USDA but is approved for use as an Experimental Vaccine. USDA licensed vaccines have to be produced in a USDA licensed facility and that vaccine has to go through the USDA licensing procedure. There are no USDA licensed facilities in Louisiana. The Experimental Vaccine that we produce employs the same purification procedure as did Mallinckrodt's Plazvax. Our vaccine uses the same strain of Anaplasma marginale that was used in Plazvax. Our vaccine has provided good protection against Bovine Anaplasmosis in the United States and Puerto Rico. We have never had a case of Neonatal Isoerythrolysis reported in calves of vaccinated cows. The vaccine has been used in cows in all stages of pregnancy with no problems being reported.  The USDA has not carried out efficacy or potency test on this experimental vaccine.

We have marketed hundreds of thousands of doses of our Experimental Anaplasmosis Vaccine since early in 2000. To this point the only complaint we have had regarding the vaccine was the first vaccine was very thick and hard to use. The first vaccine we produced was mixed in an omni blender, which made it very thick. We have since homogenized the vaccine as did Mallinckrodt and it is now about the thickness of milk.

If you are interested in obtaining the vaccine, we would be pleased to discuss and answer any questions that you might have. We can be contacted by multiple means as stated at the top of this page.
E-mail D. Gene Luther, D.V.M., Ph.D.